微创医疗(00853.HK)：合并CRM Cayman预计12月19日前后完成

Core Viewpoint - MicroPort Medical (00853.HK) has announced that independent shareholders approved the merger agreement with CRM Cayman, expected to be completed around December 19, 2025. This merger aims to integrate resources in the structural heart disease and arrhythmia management sectors, optimizing product lines and global channels to jointly expand the heart failure management market [1]. Financial Impact - The merger will eliminate approximately $260 million in preferred stock buyback obligations, thereby optimizing the debt structure [1]. - CRM Cayman has successfully refinanced a $128 million convertible bond into a mid-term bank loan with an interest rate of 2.8%, further alleviating debt burden [1].